Empirico Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
72
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$69.2M
- Investors
-
5
Empirico General Information
Description
Developer of siRNA-based therapeutics designed to target and treat diseases by leveraging naturally occurring genetic variants. The company offers proprietary platforms for genetically validated target discovery and siRNA drug development, enabling pharmaceutical and biotechnology partners to advance treatments for patients with unmet medical needs.
Contact Information
Website
www.empiri.coCorporate Office
- 10955 Vista Sorrento Parkway
- Suite 130
- CA 92130
- United States
Corporate Office
- 10955 Vista Sorrento Parkway
- Suite 130
- CA 92130
- United States
Empirico Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 20-Mar-2023 | $69.2M | Completed | Clinical Trials - Phase 1 | ||
| 2. Early Stage VC (Series A2) | 20-Dec-2019 | Completed | Pre-Clinical Trials | |||
| 1. Early Stage VC (Series A) | 01-Nov-2018 | $12.5M | $12.5M | Completed | Pre-Clinical Trials |
Empirico Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | 426,540 | $0.000010 | $0.1 | $1.29 | $1.29 | 1x | $1.29 | 1.02% |
| Series A | 7,445,092 | $0.000010 | $0.13 | $1.61 | $1.61 | 1x | $1.61 | 17.8% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Empirico Comparisons
Industry
Financing
Details
Empirico Competitors (7)
One of Empirico’s 7 competitors is Arrowhead Pharmaceuticals, a Corporation company based in Pasadena, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | ||||
| Silence Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA |
Empirico Patents
Empirico Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026222326-A1 | Treatment of lung related diseases and disorders | Pending | 17-Apr-2025 | ||
| WO-2026193191-A2 | Modified oligonucleotides | Pending | 13-Mar-2025 | ||
| WO-2026164975-A1 | Treatment of plg related diseases and disorders | Pending | 28-Jan-2025 | ||
| WO-2026122565-A1 | Treatment of fgg related diseases and disorders | Pending | 04-Dec-2024 | ||
| WO-2026090085-A1 | Treatment of cd33 related diseases and disorders | Pending | 21-Oct-2024 | A61P25/28 |
Empirico Signals
Empirico Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbCellera Biologics | Corporation | Minority | ||
| Qiming Venture Partners USA | Venture Capital | Minority | ||
| Ionis Pharmaceuticals | Corporation | Minority | ||
| DCVC Bio | Venture Capital | Minority | ||
| Neotribe Ventures | Venture Capital | Minority |
Empirico FAQs
-
When was Empirico founded?
Empirico was founded in 2017.
-
Where is Empirico headquartered?
Empirico is headquartered in CA.
-
What is the size of Empirico?
Empirico has 72 total employees.
-
What industry is Empirico in?
Empirico’s primary industry is Biotechnology.
-
Is Empirico a private or public company?
Empirico is a Private company.
-
What is the current valuation of Empirico?
The current valuation of Empirico is .
-
What is Empirico’s current revenue?
The current revenue for Empirico is .
-
How much funding has Empirico raised over time?
Empirico has raised $98.8M.
-
Who are Empirico’s investors?
AbCellera Biologics, Qiming Venture Partners USA, Ionis Pharmaceuticals, DCVC Bio, and Neotribe Ventures have invested in Empirico.
-
Who are Empirico’s competitors?
Arrowhead Pharmaceuticals, Silence Therapeutics, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, and Ionis Pharmaceuticals are some of the 7 competitors of Empirico.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process